30
2020-12
Suzhou, Dec. 30, 2020--Kintor Pharmaceutical Limited is pleased to announce that it took only more than three months for the Company to complete the enrolment of 120 patients required for the Phase II clinical trial for Pyrilutamide (tincture） for the treatment of androgenetic alopecia since its launch in September this year, which is being developed by the Company as a potential first-in-class drug.
30
2020-12
Kintor Pharmaceutical Won the Award of Futu Annual Best Investor Relations Hong Kong-listed Company
Suzhou, Dec. 29, 2020----Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the company won the Award of the Best Investor Relations Hong Kong-listed Company in the 2020 Annual Review of the Community of Futubull held by Futu recently, which was also the first time for the company to win this award.
20
2020-12
Kintor Pharma's shares have been included in FTSE Index
Suzhou, Dec. 20, 2020--Kintor Pharmaceutical Limited is pleased to announce that the company‘s shares have been included in FTSE Global Equity Index Series micro-cap index, with effective after the close of business on December 18.
11
2020-12
Preliminary Results from the Proxalutamide's COVID-19 Trial
Suzhou, Dec. 11, 2020--Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the Clinical Trial of Proxalutamide for the treatment of COVID-19.
09
2020-12
Kintor to Present Results of GT90001 and Opdivo Combo Study at 2021 ASCO GI
On December 9, 2020, Kintor has announced to present results of GT90001 and Opdivo combo study at 2021 ASCO GI.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn